Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy

Nature Communications

Volumn 8, Issue , 2017, Pages

  Liu, Zuqiang ^a,b   Ravindranathan, Roshni ^a,b   Kalinski, Pawel ^a,b   Guo, Z Sheng ^a,b   Bartlett, David L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANZYME B; MONOCLONAL ANTIBODY; PERFORIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; UNCLASSIFIED DRUG; VACCINIA VACCINE; CD274 PROTEIN, HUMAN;

CANCER; DISEASE TREATMENT; IMMUNE RESPONSE; INFILTRATION; TUMOR; VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON CANCER; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARIAN CANCER CELL LINE; OVARY CANCER; POXVIRIDAE; T LYMPHOCYTE; VACCINIA VIRUS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE; UPREGULATION;

POXVIRIDAE; VACCINIA VIRUS;

ANIMALS; B7-H1 ANTIGEN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTERFERON-GAMMA; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY; UP-REGULATION; VACCINIA VIRUS;

EID: 85016152800     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14754     Document Type: Article

References (48)

1. Bartlett, D. L., et al. Oncolytic viruses as therapeutic cancer vaccines. Mol. Cancer 12, 103 (2013).
2. Lichty, B. D., Breitbach, C. J., Stojdl, D. F., Bell, J. C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 14, 559-567 (2014).
3. Andtbacka, R. H., et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J. clin. oncol. 33, 2780-2788 (2015).
4. Mellman, I., Coukos, G., Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480-489 (2011).
5. Schlom, J. Therapeutic cancer vaccines: current status and moving forward. J. Natl. Cancer Inst. 104, 599-613 (2012).
6. Restifo, N. P., Dudley, M. E., Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. rev. Immunol. 12, 269-281 (2012).
7. Barrett, D. M., Singh, N., Porter, D. L., Grupp, S. A., June, C. H. Chimeric antigen receptor therapy for cancer. Annu. rev. med. 65, 333-347 (2014).
8. Topalian, S. L., Taube, J. M., Anders, R. A., Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. rev. Cancer 16, 275-287 (2016).
9. Melero, I., et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. rev. Cancer 15, 457-472 (2015).
10. Kaufman, H. L., Kohlhapp, F. J., Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642-662 (2015).
11. Kirn, D. H., Thorne, S. H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. rev. Cancer 9, 64-71 (2009).
12. Kaufman, H. L., et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7. 1 for the treatment of melanoma. J. clin. invest. 115, 1903-1912 (2005).
13. Chard, L. S., Lemoine, N. R., Wang, Y. New role of interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer. Oncoimmunology 4, e1038689 (2015).
14. Liu, Z., et al. CXCL11-armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. Oncoimmunology 5, e1091554 (2016).
15. Heo, J., et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. med. 19, 329-336 (2013).
16. Zeh, H. J., et al. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, antitumor activity. Mol. Ther. 23, 202-214 (2015).
17. Downs-Canner, S., et al. Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers. Mol. Ther. 24, 1492-1501 (2016).
18. Francis, L., et al. Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Oncotarget 7, 22174-22185 (2016).
19. Dong, H., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. med. 8, 793-800 (2002).
20. Freeman, G. J., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
21. Barber, D. L., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
22. Shin, H., Wherry, E. J. CD8 T cell dysfunction during chronic viral infection. Curr. opin. immunol. 19, 408-415 (2007).
23. Topalian, S. L., Drake, C. G., Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450-461 (2015).
24. Muhlbauer, M., et al. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and-gamma and mediates T cell apoptosis. J. Hepatol. 45, 520-528 (2006).
25. Green, M. R., et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin. Cancer Res. 18, 1611-1618 (2012).
26. Lu, W., et al. Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression. Oncol. Lett. 5, 1519-1526 (2013).
27. Abiko, K., et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br. J. Cancer 112, 1501-1509 (2015).
28. Chen, L., Han, X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, future. J. clin. invest. 125, 3384-3391 (2015).
29. Fortin, C., Huang, X., Yang, Y. NK cell response to vaccinia virus is regulated by myeloid-derived suppressor cells. J. Immunol. 189, 1843-1849 (2012).
30. Jiang, Y., Li, Y., Zhu, B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 6, e1792 (2015).
31. Speiser, D. E., Ho, P. C., Verdeil, G. Regulatory circuits of T cell function in cancer. Nat. rev. Immunol. 16, 599-611 (2016).
32. Brahmer, J. R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. j. med. 366, 2455-2465 (2012).
33. Herbst, R. S., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
34. Dias, J. D., et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther. 19, 988-998 (2012).
35. Engeland, C. E., et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol. Ther. 22, 1949-1959;2014
36. Zamarin, D., et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. transl. med. 6, 226ra232 (2014).
37. Quetglas, J. I., et al. Virotherapy with a Semliki Forest virus-based vector encoding IL12 synergizes with PD-1/PD-L1 blockade. Cancer Immunol. Res. 3, 449-454 (2015).
38. Rajani, K., et al. Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol. Ther. 24, 166-174 (2016).
39. Woller, N., et al. Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol. Ther. 23, 1630-1640 (2015).
40. Noman, M. Z., et al. PD-L1 is a novel direct target of HIF-1alpha, its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781-790 (2014).
41. Flies, D. B., Chen, L. The new B7s: playing a pivotal role in tumor immunity. J. Immunother. 30, 251-260 (2007).
42. Keir, M. E., Butte, M. J., Freeman, G. J., Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
43. Guo, Z. S., Liu, Z., Bartlett, D. L. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front. oncol. 4, 74 (2014).
44. Breitbach, C. J., et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer res. 73, 1265-1275 (2013).
45. Kleffel, S., et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162, 1242-1256 (2015).
46. Kuang, D. M., et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206, 1327-1337 (2009).
47. Chalikonda, S., et al. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther. 15, 115-125 (2008).
48. Li, Q., O'Malley, M. E., Bartlett, D. L., Guo, Z. S. Homeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growth. Mol. cancer 10, 63 (2011).